Shanghai Fosun Pharmaceutical (Group) Co (08HH) Price & Analysis

0 Followers

08HH Stock Chart & Stats

€1.80

€0.03(1.75%)

At close: Jul 29 4:00 PM EDT

€1.80

€0.03(1.75%)

Day’s Range― - ―

52-Week Range€1.66 - €3.22

Previous CloseN/A

Volume0.00

Average Volume (3M)800.00

Market Cap

€6.86B

Enterprise Value€78.25K

Total Cash (Recent Filing)€16.31B

Total Debt (Recent Filing)€39.45B

Price to Earnings (P/E)16.9

Beta0.26

Next Earnings

Nov 03, 2026

EPS Estimate

0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.90

Shares Outstanding551,940,500

10 Day Avg. Volume1,600

30 Day Avg. Volume800

Financial Highlights & Ratios

PEG Ratio0.74

Price to Book (P/B)0.95

Price to Sales (P/S)1.15

P/FCF Ratio60.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€2.46

Price Target Upside36.76% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.16

Revenue Forecast (FY)€4.71B

Bulls Say, Bears Say

Bulls Say

Revenue ReboundThe strong TTM revenue rebound indicates improved demand, pricing, or product mix after several softer years. If sustained, this renewed top-line momentum can support greater scale, reinforce market reach, and provide a stronger base for funding product and commercial investments.

Solid Gross ProfitabilityA gross margin near 49% demonstrates meaningful value capture across the company’s pharmaceutical activities, while the positive net margin confirms that revenue converts into earnings. Sustained profitability should support reinvestment and resilience across the group’s healthcare businesses.

Diversified Healthcare PlatformFosun Pharma’s presence across manufacturing, distribution, medical services, devices, and diagnostics creates a broad healthcare platform rather than reliance on one activity. This breadth supports multiple revenue channels and gives the group several avenues for longer-term expansion.

Bears Say

Higher LeverageThe increase in debt-to-equity means expansion is being funded with more borrowing, reducing balance-sheet flexibility. Higher leverage can constrain future investment choices and leave less capacity to absorb operating weakness while interest and refinancing obligations remain.

Uneven Free Cash FlowPositive TTM free cash flow is encouraging, but the recent decline and history of negative generation show that earnings have not converted consistently into discretionary cash. This limits internally funded growth and is more consequential alongside the company’s higher leverage.

Operating Margin VolatilityThe lower EBIT margin versus the 2024 peak suggests that cost pressure or mix effects have reduced operating leverage. Continued volatility could limit the amount of revenue growth reaching shareholders and make sustainable earnings performance less predictable.

Shanghai Fosun Pharmaceutical (Group) Co News

Fosun Pharma Wins China Trial Nod for Vitiligo Drug FXS5626

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) just unveiled an announcement. Shanghai Fosun Pharmaceutical said its subsidiary...

5d ago

Fosun Pharma Launches Up to HK$1 Billion H-Share Buyback Plan

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical has...

7d ago

Fosun Pharma Wins China Approval for New Luvometinib Indication

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical said its subsidiary,...

10d ago

Fosun Pharma Grants Reserved A Share Options Under 2025 Incentive Scheme

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical has...

16d ago

Fosun Pharma Grants New H Share RSUs to 100 Employees Under 2025 Incentive Scheme

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an announcement. Shanghai Fosun Pharmaceutical has approved a...

16d ago

Fosun Pharma Unit Secures Exclusive Rights to Advanced Bispecific Antibody Drug

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical has announced that...

17d ago

Shanghai Fosun Pharma Executes HK$3.6 Million H-Share Buyback

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an update. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

17d ago

Fosun Pharma Posts Modest Profit Growth in First-Half 2026 Results

The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ). Shanghai Fosun Pharmaceutical (Group)...

19d ago

Shanghai Fosun Pharmaceutical (Group) Co Class H (SFOSF) Q2 Earnings Cheat Sheet

Shanghai Fosun Pharmaceutical (Group) Co Class H (SFOSF) is scheduled to report 2nd quarter earnings on 08/25/2026. Regarding...

21d ago

Fosun Pharma Subsidiary Advances COPD Drug FXS7553 Into Phase II Trial in China

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an announcement. Shanghai Fosun Pharmaceutical has announced that...

1M ago

Shanghai Fosun downgraded to Hold from Buy at HSBC

HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The...

3y ago

Syneos Health partners with Fosun Pharma USA to launch serplulimab

Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos...

4y ago

SYNH

08HH FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was €1.66 and its highest was €3.22 in the past 12 months.

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is €6.86B.

When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Nov 03, 2026 which is in 51 days.

How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Aug 25, 2026. The company reported €0.041 earnings per share for the quarter, missing the consensus estimate of €0.046 by -€0.005.

Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?

According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H does not currently pay dividends.

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.04.

How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.

What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of €0.041 in its last earnings report, missing expectations of €0.046. Following the earnings report the stock price went down -1.396%.

Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?

Currently, no hedge funds are holding shares in DE:08HH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

Outperform

Fundamentals

Return on Equity

2.74%

Trailing 12-Months

Asset Growth

11.60%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co (08HH) Earnings & Revenues

Historic Earnings Reports

08HH Stock 12 Month Forecast

Average Price Target

€2.46

▲(36.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","3":"€3","0.75":"€0.75","1.5":"€1.5","2.25":"€2.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.9167166,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4616649500000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.0066133,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,0.75,1.5,2.25,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.764,1.8526705076923078,1.9413410153846153,2.030011523076923,2.118682030769231,2.2073525384615387,2.296023046153846,2.384693553846154,2.4733640615384616,2.5620345692307693,2.650705076923077,2.7393755846153844,2.8280460923076927,{"y":2.9167166,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.764,1.8176665346153846,1.8713330692307693,1.9249996038461539,1.9786661384615385,2.0323326730769233,2.085999207692308,2.1396657423076926,2.193332276923077,2.246998811538462,2.3006653461538464,2.354331880769231,2.4079984153846157,{"y":2.4616649500000003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.764,1.7826625615384615,1.8013251230769232,1.8199876846153846,1.8386502461538463,1.8573128076923078,1.8759753692307692,1.894637930769231,1.9133004923076924,1.9319630538461539,1.9506256153846155,1.969288176923077,1.9879507384615387,{"y":2.0066133,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.472,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.664,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.522,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.294,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.039,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.053,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.999,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.141,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.998,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.803,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.625,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.804,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.764,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >